Ali Samii

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi request reprint NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies
    Ali Samii
    Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center, Seattle, Washington, USA
    Drugs Aging 26:769-79. 2009
  2. doi request reprint Statin use and the risk of Parkinson disease: a nested case control study
    Ali Samii
    Department of Neurology, University of Washington, Seattle VA Parkinson Disease Research Education and Clinical Center PADRECC, VA Puget Sound Health Care System, 1660 S Columbian Way, MS 127, Seattle, WA 98108, USA
    J Clin Neurosci 15:1272-3. 2008
  3. ncbi request reprint Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson disease
    Ali Samii
    Department of Neurology, University of Washington, Seattle, Washington, USA
    Mov Disord 22:1476-81. 2007
  4. ncbi request reprint Spinal accessory neuropathy after deep brain stimulation for Parkinson's disease
    Ali Samii
    Department of Neurology, University of Washington, Seattle, WA 98108, USA
    Stereotact Funct Neurosurg 85:296-8. 2007
  5. ncbi request reprint Telemedicine for delivery of health care in Parkinson's disease
    Ali Samii
    Department of Neurology and Seattle Parkinson Disease Research Education and Clinical Center Seattle PADRECC, VA Puget Sound Health Care System, Seattle, Washington 98108, USA
    J Telemed Telecare 12:16-8. 2006
  6. ncbi request reprint Deep brain stimulation in a patient on immunosuppressive therapy after renal transplant
    Ali Samii
    VAPSHCS, Department of Neurology, University of Washington, 1660 S Columbian Way, Mailstop 127, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 11:259-60. 2005
  7. ncbi request reprint Parkinson's disease
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
    Lancet 363:1783-93. 2004
  8. ncbi request reprint Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
    Mov Disord 18:1556-8. 2003
  9. ncbi request reprint Bilateral subthalamic nucleus stimulation after bilateral pallidotomies in a patient with advanced Parkinson's disease
    Ali Samii
    Department of Neurology, Seattle VA Puget Sound Health Care System, 1660 South Columbian Way, MS 127 S, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 9:159-62. 2003
  10. ncbi request reprint Unilateral subthalamic nucleus deep brain stimulation contralateral to thalamic stimulation in Parkinson disease
    Ali Samii
    VAPSHCS, Department of Neurology, University of Washington School of Medicine, Mailstop 127, 1660 S Columbian Way, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 11:257-8. 2005

Detail Information

Publications44

  1. doi request reprint NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies
    Ali Samii
    Department of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center, Seattle, Washington, USA
    Drugs Aging 26:769-79. 2009
    ..Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD)...
  2. doi request reprint Statin use and the risk of Parkinson disease: a nested case control study
    Ali Samii
    Department of Neurology, University of Washington, Seattle VA Parkinson Disease Research Education and Clinical Center PADRECC, VA Puget Sound Health Care System, 1660 S Columbian Way, MS 127, Seattle, WA 98108, USA
    J Clin Neurosci 15:1272-3. 2008
    ..94 (0.82-1.09). Our study did not show a statistically significant effect on the risk of PD with statin use...
  3. ncbi request reprint Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson disease
    Ali Samii
    Department of Neurology, University of Washington, Seattle, Washington, USA
    Mov Disord 22:1476-81. 2007
    ..Most of the improvements in off-medication ADL scores, dyskinesia scores, complications of therapy, and medication dose reduction occurred after unilateral STN stimulation with smaller improvements after the second operation...
  4. ncbi request reprint Spinal accessory neuropathy after deep brain stimulation for Parkinson's disease
    Ali Samii
    Department of Neurology, University of Washington, Seattle, WA 98108, USA
    Stereotact Funct Neurosurg 85:296-8. 2007
    ..As a result of this complication, we now map the spinal accessory nerve electrophysiologically during deep brain stimulation surgery...
  5. ncbi request reprint Telemedicine for delivery of health care in Parkinson's disease
    Ali Samii
    Department of Neurology and Seattle Parkinson Disease Research Education and Clinical Center Seattle PADRECC, VA Puget Sound Health Care System, Seattle, Washington 98108, USA
    J Telemed Telecare 12:16-8. 2006
    ..Our experience shows that telemedicine can be used effectively for follow-up visits with selected PD patients who are unable to travel...
  6. ncbi request reprint Deep brain stimulation in a patient on immunosuppressive therapy after renal transplant
    Ali Samii
    VAPSHCS, Department of Neurology, University of Washington, 1660 S Columbian Way, Mailstop 127, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 11:259-60. 2005
    ..DBS surgery may be safely performed in carefully selected patients on systemic immunosuppression after renal transplant...
  7. ncbi request reprint Parkinson's disease
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
    Lancet 363:1783-93. 2004
    ..This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis...
  8. ncbi request reprint Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
    Mov Disord 18:1556-8. 2003
    ..We report on details of a movement disorder that followed anti-B-cell therapy in a patient with lymphoma, and was accompanied by CRMP-5 IgG...
  9. ncbi request reprint Bilateral subthalamic nucleus stimulation after bilateral pallidotomies in a patient with advanced Parkinson's disease
    Ali Samii
    Department of Neurology, Seattle VA Puget Sound Health Care System, 1660 South Columbian Way, MS 127 S, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 9:159-62. 2003
    ..The presence of cervical myelopathy and the limited response to anti-Parkinson medications in this patient underscores the importance of patient selection for functional neurosurgery in PD...
  10. ncbi request reprint Unilateral subthalamic nucleus deep brain stimulation contralateral to thalamic stimulation in Parkinson disease
    Ali Samii
    VAPSHCS, Department of Neurology, University of Washington School of Medicine, Mailstop 127, 1660 S Columbian Way, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 11:257-8. 2005
    ..However, there was no significant improvement in activities of daily living (ADL), motor scores in the medication ON state, gait, or postural stability...
  11. pmc Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease
    Carolyn M Hutter
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Eur J Neurol 15:134-9. 2008
    ..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease...
  12. pmc Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Ann Neurol 62:137-44. 2007
    ..We sought to replicate these findings...
  13. pmc SNCA variant associated with Parkinson disease and plasma alpha-synuclein level
    Ignacio F Mata
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Mailstop S 182, 1660 S Columbian Way, Seattle, WA 98108, USA
    Arch Neurol 67:1350-6. 2010
    ..A functional repeat polymorphism in the SNCA promoter (REP1) conveys susceptibility for Parkinson disease (PD). There is also increasing evidence that single-nucleotide polymorphisms (SNPs) elsewhere in the gene are associated with PD risk...
  14. pmc Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders
    Ignacio F Mata
    Department of Neurology, University of Washington School of Medicine, Seattle, USA
    Arch Neurol 65:379-82. 2008
    ..However, these findings have not been consistently replicated, and most studies have had substantial methodological shortcomings...
  15. pmc Risk prediction for complex diseases: application to Parkinson disease
    Taryn O Hall
    Institute for Public Health Genetics, University of Washington, Seattle, WA 98109, USA
    Genet Med 15:361-7. 2013
    ..Genet Med 2013:15(5):361-367...
  16. ncbi request reprint Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
    Karen M Powers
    Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
    Mov Disord 23:88-95. 2008
    ..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated...
  17. pmc Association mapping of the PARK10 region for Parkinson's disease susceptibility genes
    Jia Y Wan
    Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
    Parkinsonism Relat Disord 20:93-8. 2014
    ..Previous studies indicate that as many as six genes within the PARK10 region (RNF11, UQCRH, HIVEP3, EIF2B3, USP24, ELAVL4) might modify susceptibility or age at onset in Parkinson's disease (PD)...
  18. doi request reprint Assessing the effects of subthalamic nucleus stimulation on gait and mobility in people with Parkinson disease
    Valerie E Kelly
    Department of Rehabilitation Medicine, University of Washington, Seattle, Washington 98195 6490, USA
    Disabil Rehabil 32:929-36. 2010
    ..To determine the effects of unilateral and bilateral subthalamic nucleus (STN) stimulation on gait and mobility in persons with Parkinson disease (PD)...
  19. pmc Common variation in the LRRK2 gene is a risk factor for Parkinson's disease
    Ignacio F Mata
    Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, USA
    Mov Disord 27:1822-5. 2012
    ..Common variants in the LRRK2 gene influence the risk of Parkinson's disease (PD) in Asians, but whether the same is true in European-derived populations is less clear...
  20. pmc A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity
    Parvoneh Poorkaj
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, USA
    Mov Disord 25:1409-17. 2010
    ..In conclusion, we have identified a unique X-linked parkinsonian syndrome with variable spasticity and four-repeat tau pathology, and defined a novel candidate gene locus spanning approximately 28 Mb from Xp11.2-Xq13.3...
  21. ncbi request reprint Gait changes in response to subthalamic nucleus stimulation in people with Parkinson disease: a case series report
    Valerie E Kelly
    Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA
    J Neurol Phys Ther 30:184-94. 2006
    ..The purpose of this paper is to describe the effects of unilateral and bilateral STN stimulation on gait following staged stimulator implantations in a series of individuals with PD...
  22. pmc DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease
    Lani S Chun
    Department of Neurology, University of Washington School of Medicine, Seattle, WA 98108, USA
    Ann Neurol 62:99-101. 2007
    ..Furthermore, we found no evidence for an effect of genotype on age at onset among patients. Our findings argue against DBH -1021C-->T as a risk factor or age at onset modifier in PD...
  23. ncbi request reprint Mechanical failure of the electrode wire in deep brain stimulation
    A Alex Mohit
    Department of Neurological Surgery, University of Washington School of Medicine, Seattle, WA 98108, USA
    Parkinsonism Relat Disord 10:153-6. 2004
    ..The fact that all breakages occurred near the connection wire suggests that to-and-fro motion of the DBS electrode with repeated head turning leads to fatigue and eventual disruption...
  24. doi request reprint Exploring gene-environment interactions in Parkinson's disease
    Colin C McCulloch
    Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
    Hum Genet 123:257-65. 2008
    ..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk...
  25. doi request reprint Longitudinal diffusion tensor imaging in Huntington's Disease
    Kurt E Weaver
    Department of Radiology, University of Washington School of Medicine, Box 357115, Seattle, WA 98195, USA
    Exp Neurol 216:525-9. 2009
    ..These results suggest that longitudinal FA changes may serve as a neuropathological biomarker in HD...
  26. doi request reprint Recurrent transient global amnesia with intrathecal baclofen
    Lucinda A Grande
    Department of Anesthesiology, Box 356540, University of Washington School of Medicine, Seattle, WA 98195, USA
    Anesth Analg 106:1284-7, table of contents. 2008
    ..Baclofen-induced amnesia in rodents is a reliable model of memory impairment. In contrast, baclofen-induced memory impairment in humans is uncommon. Baclofen- associated transient global amnesia has not previously been reported...
  27. ncbi request reprint Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics
    Denise M Kay
    Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
    Mov Disord 21:519-23. 2006
    ..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date...
  28. doi request reprint Genetic association between alpha-synuclein and idiopathic Parkinson's disease
    Denise M Kay
    New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
    Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008
    ..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD...
  29. ncbi request reprint The youngest reported case of corticobasal degeneration
    Anna DePold Hohler
    Department of Neurology, Madigan Army Medical Center, Tacoma, WA, USA
    Parkinsonism Relat Disord 10:47-50. 2003
    ..The chronic, progressive course, asymmetric limb rigidity, apraxia, focal dystonia, and lack of response to levodopa suggest CBD. To our knowledge, this is the youngest reported case of clinically probable CBD...
  30. pmc LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago
    Cyrus P Zabetian
    Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
    Am J Hum Genet 79:752-8. 2006
    ..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas...
  31. ncbi request reprint Multisite randomized trial of deep brain stimulation
    Kenneth Follett
    Arch Neurol 62:1643-4; author reply 1644-5. 2005
  32. pmc Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study
    Alexis Elbaz
    INSERM, Unit 708, Paris, France
    Lancet Neurol 5:917-23. 2006
    ..Small-scale replication studies were largely non-confirmatory, but a meta-analysis that included data from the original study could not exclude all SNP associations, leaving relevance of several markers uncertain...
  33. ncbi request reprint Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease
    Denise M Kay
    Wadsworth Center, New York State Department of Health, Albany, NY 12201 2002, USA
    Genet Test 10:221-7. 2006
    ..Test results can have psychological, social, and economical ramifications; thus, proper counseling is essential...
  34. ncbi request reprint Holmes-like tremor of the lower extremity following brainstem hemorrhage
    Melanie Walker
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
    Mov Disord 22:272-4. 2007
    ..Tremor involving the lower extremity in this setting has not been previously reported...
  35. ncbi request reprint Chronic severe dystonia after single exposure to antiemetics
    Melanie Walker
    Department of Neurology, University of Washington, Seattle, 98104, USA
    Am J Emerg Med 24:125-7. 2006
  36. ncbi request reprint Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders
    Fadi Abdi
    Applied Biosystems, Framingham, MA, USA
    J Alzheimers Dis 9:293-348. 2006
    ....
  37. doi request reprint Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study
    Mahyar Etminan
    Center for Clinical Epidemiology and Evaluation, Vancouver General Hospital, Vancouver, British Columbia, Canada
    J Clin Neurosci 15:576-7. 2008
    ..A time-dependent Cox model was used to estimate adjusted rate ratios for users and non-users of NSAIDs. The results of our study did not show a protective effect of NSAIDs for PD (rate ratio 0.84, 95% CI 0.81-1.09)...
  38. pmc Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies
    Mahyar Etminan
    Division of Epidemiology, Royal Victoria and Vancouver Hospitals, Canada
    BMJ 330:63. 2005
    ..To explore the association between migraine and risk of ischaemic stroke...
  39. ncbi request reprint Statin therapy and risk of dementia in the elderly
    Mahyar Etminan
    Neurology 64:1319; author reply 1319. 2005
  40. pmc Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
    Mahyar Etminan
    Department of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A1
    BMJ 327:128. 2003
    ..To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use...
  41. ncbi request reprint Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis
    Mahyar Etminan
    Division of Clinical Epidemiology, Royal Victoria Hospital and McGill University, Montreal, Quebec, Canada
    Lancet Neurol 4:362-5. 2005
    ..We conclude that dietary vitamin E may have a neuroprotective effect attenuating the risk of PD. These results require confirmation in randomised controlled trials...
  42. ncbi request reprint Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making
    Mahyar Etminan
    Center for Clinical Epidemiology and Evaluation, Vancouver Hosptial, 7th Floor, 828 West 10th Avenue, Vancouver, B C, Canada
    J Clin Pharmacol 46:6-9. 2006
    ..We also discuss the potential problem of discordant results and urge pharmacoepidemiologists to develop good practice guidelines for the conduct of pharmacoepidemiologic studies...
  43. ncbi request reprint Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis
    Mahyar Etminan
    Kunin Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario, Canada
    Drug Saf 26:439-44. 2003
    ..There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug.Objective: To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature...
  44. ncbi request reprint Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs
    Mahyar Etminan
    Division of Clinical Epidemiology, Royal Victoria Hospital, and McGill Health Centre, Montreal, Quebec, Canada
    Pharmacotherapy 24:964-9. 2004
    ....